IBO Graph | Impact BioMedical, INC.

IBO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $3.00K; Cost of revenue $1.00K; Research and development $76.00K; Selling, general and administrative $167.00K.
2026-03-31: Revenue $7.00K; Cost of revenue (m); Research and development $46.00K; Selling, general and administrative $1.62M.
2025-12-31: Revenue $7.00K*; Cost of revenue $422.00K*; Research and development $110.00K*; Selling, general and administrative $118.00K*.
2025-09-30: Revenue $18.00K; Cost of revenue $1.00K; Research and development $52.00K; Selling, general and administrative $261.00K.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2026-06-30	$3.00K	$1.00K	$76.00K	$167.00K	(m)	(m)	-$699.00K
2026-03-31	$7.00K	(m)	$46.00K	$1.62M	(m)	(m)	-$2.29M
2025-12-31	$7.00K*	$422.00K*	$110.00K*	$118.00K*	(m)	(m)	$5.25M*
2025-09-30	$18.00K	$1.00K	$52.00K	$261.00K	(m)	(m)	-$1.47M
2025-06-30	$7.00K	$1.00K	$75.00K	$246.00K	(m)	(m)	-$14.35M
2025-03-31	(m)	(m)	$103.00K	$248.00K	$1.01M	(m)	-$1.27M
2024-12-31	(m)	(m)	(m)	(m)	$26.23M*	(m)	(m)
2024-09-30	(m)	(m)	$82.00K	$132.00K	$1.13M	(m)	$4.25M
2024-06-30	(m)	(m)	$121.00K	$145.00K	$626.00K	(m)	-$889.00K
2024-03-31	(m)	(m)	$183.00K	$148.00K	$771.00K	(m)	-$962.00K
2023-09-30	(m)	(m)	$357.00K	$101.00K	$1.08M	(m)	-$1.18M
2023-06-30	(m)	(m)	$266.00K	$41.00K	$1.01M	(m)	-$1.12M
2023-03-31	(m)	(m)	$179.00K	$40.00K	$803.00K	(m)	-$849.00K
2022-09-30	(m)	(m)	$330.00K	$90.00K	(m)	$1.26M	-$2.24M
2022-06-30	$50.00K	(m)	$206.00K	$58.00K	(m)	(m)	-$799.00K

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Net income
2026-06-30	$10.00K	$1.00K	$123.00K	$1.79M	(m)	-$2.98M
2025-06-30	$7.00K	$1.00K	$178.00K	$495.00K	(m)	-$15.61M
2024-06-30	(m)	(m)	$304.00K	$292.00K	$1.40M	-$1.85M
2023-06-30	(m)	(m)	$445.00K	$81.00K	$1.81M	-$1.97M
2022-06-30	$50.00K	(m)	$374.00K	$168.00K	(m)	-$1.54M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2025-09-30	$25.00K	$2.00K	$230.00K	$755.00K	(m)	(m)	-$17.08M
2024-09-30	(m)	(m)	$386.00K	$424.00K	$2.52M	(m)	$2.40M
2023-09-30	(m)	(m)	$1.05M	$182.00K	$2.89M	(m)	-$3.15M
2022-09-30	$50.00K	(m)	$704.00K	$286.00K	(m)	$1.26M	-$3.89M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2025-12-31	$32.00K	$424.00K	$340.00K	$873.00K	(m)	-$2.58M	-$11.84M
2024-12-31	(m)	(m)	$278.00K	$718.00K	$28.75M	$33.00K	-$24.71M
2023-12-31	(m)	(m)	$1.69M	$315.00K	$4.03M	(m)	-$4.34M
2022-12-31	$50.00K	(m)	$1.23M	$325.00K	(m)	-$621.00K	-$7.25M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Aquestive Therapeutics, Inc. (AQST)	United States	$0.606B	-6.67
CorMedix Inc. (CRMD)	United States	$0.605B	3.25
CytomX Therapeutics, Inc. (CTMX)	United States	$0.598B	-10.25
Monopar Therapeutics (MNPR)	United States	$0.598B	-34.82
Neurogene Inc. (NGNE)		$0.625B	-4.46
Altimmune, Inc. (ALT)	United States	$0.593B	-6.43
Shattuck Labs, Inc. (STTK)	United States	$0.634B	-13.30
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
Phathom Pharmaceuticals, Inc. (PHAT)	United States	$0.572B	-8.76
ZEVRA THERAPEUTICS, INC. (ZVRA)	United States	$0.668B	14.61